UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) inhibition in adults with kidney disease 2023 UPDATE
Abstract
Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney Association Clinical Practice Guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease. We provide a summary of the full guideline and highlight the rationale for recent updates. The use of SGLT-2 inhibitors in people with specific medical conditions, including type 1 diabetes, kidney transplants, and people admitted to hospital with heart failure is also considered, along with Recommendations for future research and Recommendations for implementation. A full "lay" summary of the guidelines is provided as an appendix to ensure that these guidelines are accessible and understandable to people who are not medical professionals.
Citations
Altmetric:
Date
2023-10-25
Type
Article
Subject
Acute kidney injury, Chronic kidney disease, Gliflozin, Guideline
Collections
Citation
Roddick, A. J., Wonnacott, A., Webb, D., Watt, A., Watson, M. A., Staplin, N., Riding, A., Lioudaki, E., Kuverji, A., Kossi, M. E., Holmes, P., Holloway, M., Fraser, D., Carvalho, C., Burton, J. O., Bhandari, S., Herrington, W. G., & Frankel, A. H. (2023). UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE. BMC nephrology, 24(1), 310. https://doi.org/10.1186/s12882-023-03339-3